[{"id":"f30ecff2-7653-43cc-b571-141733c1cb0d","acronym":"TWT-101","url":"https://clinicaltrials.gov/study/NCT04521413","created_at":"2021-01-18T21:39:25.557Z","updated_at":"2024-07-02T16:35:10.432Z","phase":"Phase 1/2","brief_title":"Safety and Efficacy Study of CFI-402411 in Subjects With Advanced Solid Malignancies","source_id_and_acronym":"NCT04521413 - TWT-101","lead_sponsor":"Treadwell Therapeutics, Inc","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • CFI-402411"],"overall_status":"Recruiting","enrollment":" Enrollment 170","initiation":"Initiation: 08/31/2020","start_date":" 08/31/2020","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2024-04-10"}]